Lung Cancer
Imfinzi
Indication
IMFINZI® is a programmed death-ligand 1 (PD-L1)blocking antibody indicated:
• for the treatment of adult patients with unresectable,Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
• in combination with etoposide and either carboplatin or cisplatin,as first-line treatment of adult patients with extensive-stage small-cell lung cancer.
Imfinzi CASPIAN trial summary (Extensive-stage small-cell lung cancer)
Imfinzi PACIFIC trial 5-year analysis update summary (Stage III unresectable non-small cell lung cancer)
Loading......
Mode of action
Please add text for Promomat
IMFINZI®(Durvalumab) is an immunotherapy blocks PD-L1 and reinvigorates T-cells.
Instructions:
10 mg/kg administrated as an intravenous infusion over 60 mins every 2 weeks until disease progression or unacceptable toxicity.
Contraindications, warnings and precautions
Contraindications:
None.
Precautions:
Immune-Mediated Pneumonitis: Withhold for moderate and permanently discontinue for severe or life-threatening pneumonitis. Immune-Mediated Hepatitis: Monitor for changes in liver function. Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation. Immune-Mediated Colitis: Withhold for moderate and permanently discontinue for severe or life-threatening colitis. Immune-Mediated Endocrinopathies: Withhold for moderate, severe or life-threatening. Immune-Mediated Nephritis: Monitor for changes in renal function. Withhold for moderate and permanently discontinue for severe or life-threatening nephritis. Immune-Mediated Dermatological Reactions: Withhold for moderate and permanently discontinue for severe or life-threatening rash. Infection: Withhold for severe or life-threatening infection. Infusion-Related Reactions: Interrupt or slow the rate of infusion for mild or moderate and permanently discontinue for severe or life-threatening infusion-related reactions. Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk toa fetus and use of effective contraception. Lactation: Advise not to breastfeed during treatment with IMFINZI and for at least 3 months after the last dose.
